Global Cardiovascular Drug Delivery Market
DUBLIN, Ireland, January 28, 2014 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/fvxjv3/cardiovascular) has announced the
addition of a new report “Global Cardiovascular Drug Delivery Market”
[http://www.researchandmarkets.com/research/fvxjv3/cardiovascular ] to their offering.
Drug delivery to the cardiovascular system is different from delivery to other systems
because of the anatomy and physiology of the vascular system; it supplies blood and
nutrients to all organs of the body. Drugs can be introduced into the vascular system for
systemic effects or targeted to an organ via the regional blood supply. In addition to the
usual formulations of drugs such as controlled release, devices are used as well. This
report starts with an introduction to molecular cardiology and discusses its relationship
to biotechnology and drug delivery systems.
Drug delivery to the cardiovascular system is approached at three levels: (1) routes
of drug delivery; (2) formulations; and finally (3) applications to various diseases.
Formulations for drug delivery to the cardiovascular system range from controlled release
preparations to delivery of proteins and peptides. Cell and gene therapies, including
antisense and RNA interference, are described in full chapters as they are the most
innovative methods of delivery of therapeutics. Various methods of improving systemic
administration of drugs for cardiovascular disorders are described including use of
Cell-selective targeted drug delivery has emerged as one of the most significant areas
of biomedical engineering research, to optimize the therapeutic efficacy of a drug by
strictly localizing its pharmacological activity to a pathophysiologically relevant tissue
system. These concepts have been applied to targeted drug delivery to the cardiovascular
system. Devices for drug delivery to the cardiovascular system are also described.
Role of drug delivery in various cardiovascular disorders such as myocardial ischemia,
hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed.
Some of the preparations and technologies are also applicable to peripheral arterial
diseases. Controlled release systems are based on chronopharmacology, which deals with the
effects of circadian biological rhythms on drug actions.A full chapter is devoted to
drug-eluting stents as treatment for restenosis following stenting of coronary
arteries.Fifteen companies are involved in drug-eluting stents.
New cell-based therapeutic strategies are being developed in response to the
shortcomings of available treatments for heart disease. Potential repair by cell grafting
or mobilizing endogenous cells holds particular attraction in heart disease, where the
meager capacity for cardiomyocyte proliferation likely contributes to the irreversibility
of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte
proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion
of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other
cells into injured myocardium.
Advances in molecular pathophysiology of cardiovascular diseases have brought gene
therapy within the realm of possibility as a novel approach to treatment of these
diseases. It is hoped that gene therapy will be less expensive and affordable because the
techniques involved are simpler than those involved in cardiac bypass surgery, heart
transplantation and stent implantation.
Key Topics Covered:
1. Cardiovascular Diseases
2. Methods for Drug Delivery to the Cardiovascular System
3. Cell Therapy for Cardiovascular Disorders
4. Gene Therapy for Cardiovascular Disorders
5. Drug-Eluting Stents
6. Markets for Cardiovascular Drug Delivery
7. Companies involved in Cardiovascular Drug Delivery
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets